Journal Article
. 2015 May; 9:519.
doi: 10.3332/ecancer.2015.519.

OECI-EACR precision medicine for cancer: Conference report 1-4 March 2015, Luxembourg

Anna Golebiewska 1 Sabrina Fritah 1 Maria Romina Girotti 2 
  • PMID: 25932043
  •     40 References


The 'Precision Medicine for Cancer' was the first meeting of a new series of conferences organised biannually by the European Association for Cancer Research (EACR) and the Organisation for European Cancer Institutes (OECI). The main objective of the meeting was to focus on novel topics in precision medicine by allowing strong interactions between participants and to access the speakers easily. As the first implementations of personalised medicine are appreciated in the clinic, the aim of the meeting was to further educate both researchers and clinicians and learn more from the novel approaches in the field. Similarly, the interaction between two organisations-the research-oriented EACR and the clinic-oriented OECI-was of a great value for the meeting. This OECI-EACR 2015 report will highlight the major findings of this outstanding meeting.

Keywords: OECI-EACR 2015; cancer; conference report; personalised medicine; precision medicine.

Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution.
Peter Eirew, Adi Steif, +43 authors, Samuel Aparicio.
Nature, 2014 Dec 04; 518(7539). PMID: 25470049    Free PMC article.
Highly Cited.
Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress.
Zachary T Schug, Barrie Peck, +30 authors, Eyal Gottlieb.
Cancer Cell, 2015 Jan 15; 27(1). PMID: 25584894    Free PMC article.
Highly Cited.
Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells.
Anna Golebiewska, Sébastien Bougnaud, +7 authors, Simone P Niclou.
Brain, 2013 Mar 06; 136(Pt 5). PMID: 23460667    Free PMC article.
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.
Sandra Misale, Sabrina Arena, +14 authors, Alberto Bardelli.
Sci Transl Med, 2014 Feb 21; 6(224). PMID: 24553387
Highly Cited.
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.
Lawrence N Kwong, James C Costello, +13 authors, Lynda Chin.
Nat Med, 2012 Sep 18; 18(10). PMID: 22983396    Free PMC article.
Highly Cited.
Next-generation sequencing of disseminated tumor cells.
Elen K Møller, Parveen Kumar, +12 authors, Vessela N Kristensen.
Front Oncol, 2014 Jan 16; 3. PMID: 24427740    Free PMC article.
Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing.
Volker Hovestadt, David T W Jones, +42 authors, Peter Lichter.
Nature, 2014 May 23; 510(7506). PMID: 24847876
Highly Cited.
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
Fei Su, Amaya Viros, +50 authors, Richard Marais.
N Engl J Med, 2012 Jan 20; 366(3). PMID: 22256804    Free PMC article.
Highly Cited.
The evolving role of cancer cell line-based screens to define the impact of cancer genomes on drug response.
Mathew J Garnett, Ultan McDermott.
Curr Opin Genet Dev, 2014 Mar 13; 24. PMID: 24607840    Free PMC article.
Mutations of the BRAF gene in human cancer.
Helen Davies, Graham R Bignell, +49 authors, P Andrew Futreal.
Nature, 2002 Jun 18; 417(6892). PMID: 12068308
Highly Cited.
Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.
Maria Romina Girotti, Filipa Lopes, +25 authors, Caroline Springer.
Cancer Cell, 2014 Dec 17; 27(1). PMID: 25500121    Free PMC article.
Highly Cited.
A new genome-driven integrated classification of breast cancer and its implications.
Sarah-Jane Dawson, Oscar M Rueda, Samuel Aparicio, Carlos Caldas.
EMBO J, 2013 Feb 12; 32(5). PMID: 23395906    Free PMC article.
Highly Cited. Review.
Molecular insights into pediatric brain tumors have the potential to transform therapy.
Amar Gajjar, Stefan M Pfister, Michael D Taylor, Richard J Gilbertson.
Clin Cancer Res, 2014 Nov 16; 20(22). PMID: 25398846    Free PMC article.
Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.
Alessio Amatu, Andrea Sartore-Bianchi, +9 authors, Salvatore Siena.
Clin Cancer Res, 2013 Feb 21; 19(8). PMID: 23422094
The multitude of molecular analyses in cancer: the opening of Pandora’s box.
Hege G Russnes, Per E Lønning, Anne-Lise Børresen-Dale, Ole C Lingjærde.
Genome Biol, 2014 Oct 16; 15(9). PMID: 25316146    Free PMC article.
Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression.
Muhammad Zaeem Noman, Bassam Janji, +8 authors, Salem Chouaib.
Cancer Res, 2011 Aug 04; 71(18). PMID: 21810913
Genome-driven integrated classification of breast cancer validated in over 7,500 samples.
H Raza Ali, Oscar M Rueda, +4 authors, Carlos Caldas.
Genome Biol, 2014 Aug 29; 15(8). PMID: 25164602    Free PMC article.
Highly Cited.
Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes.
Daniel Stieber, Anna Golebiewska, +10 authors, Simone P Niclou.
Acta Neuropathol, 2013 Oct 25; 127(2). PMID: 24154962    Free PMC article.
Critical appraisal of the side population assay in stem cell and cancer stem cell research.
Anna Golebiewska, Nicolaas H C Brons, Rolf Bjerkvig, Simone P Niclou.
Cell Stem Cell, 2011 Feb 08; 8(2). PMID: 21295271
Highly Cited.
CIP2A is an Oct4 target gene involved in head and neck squamous cell cancer oncogenicity and radioresistance.
Sami Ventelä, Eleonora Sittig, +8 authors, Jukka Westermarck.
Oncotarget, 2014 Dec 05; 6(1). PMID: 25474139    Free PMC article.
No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.
Maria Romina Girotti, Grazia Saturno, Paul Lorigan, Richard Marais.
Mol Oncol, 2014 Sep 03; 8(6). PMID: 25178978    Free PMC article.
Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality between hypoxia and DNA damage response inhibition.
Patricia A Possik, Judith Müller, +14 authors, Daniel S Peeper.
Cell Rep, 2014 Dec 03; 9(4). PMID: 25456132
The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung.
Adi F Gazdar, Trisha K Savage, +9 authors, Elisabeth Brambilla.
J Thorac Oncol, 2015 Feb 13; 10(4). PMID: 25675280    Free PMC article.
Stromal cell-induced miRNA alteration in chronic lymphocytic leukemia: how a minute and unavoidable cell contamination impairs miRNA profiling.
J Paggetti, G Berchem, E Moussay.
Leukemia, 2013 Feb 15; 27(8). PMID: 23407459
Autophagic degradation of GZMB/granzyme B: a new mechanism of hypoxic tumor cell escape from natural killer cell-mediated lysis.
Elodie Viry, Joanna Baginska, +4 authors, Bassam Janji.
Autophagy, 2013 Nov 20; 10(1). PMID: 24248158    Free PMC article.
Signatures of mutational processes in human cancer.
Ludmil B Alexandrov, Serena Nik-Zainal, +72 authors, Michael R Stratton.
Nature, 2013 Aug 16; 500(7463). PMID: 23945592    Free PMC article.
Highly Cited.
A comprehensive DNA methylation profile of epithelial-to-mesenchymal transition.
F Javier Carmona, Veronica Davalos, +19 authors, Manel Esteller.
Cancer Res, 2014 Aug 12; 74(19). PMID: 25106427
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
Christina Curtis, Sohrab P Shah, +29 authors, Samuel Aparicio.
Nature, 2012 Apr 24; 486(7403). PMID: 22522925    Free PMC article.
Highly Cited.
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
Maria R Girotti, Malin Pedersen, +12 authors, Richard Marais.
Cancer Discov, 2012 Dec 18; 3(2). PMID: 23242808    Free PMC article.
Highly Cited.
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
Sandra Misale, Rona Yaeger, +23 authors, Alberto Bardelli.
Nature, 2012 Jun 23; 486(7404). PMID: 22722830    Free PMC article.
Highly Cited.
MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia.
Etienne Moussay, Kai Wang, +8 authors, David J Galas.
Proc Natl Acad Sci U S A, 2011 Apr 05; 108(16). PMID: 21460253    Free PMC article.
Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.
Sandra Misale, Federica Di Nicolantonio, +2 authors, Alberto Bardelli.
Cancer Discov, 2014 Oct 09; 4(11). PMID: 25293556
Highly Cited. Review.
Principles and methods of integrative genomic analyses in cancer.
Vessela N Kristensen, Ole Christian Lingjærde, +3 authors, Anne-Lise Børresen-Dale.
Nat Rev Cancer, 2014 Apr 25; 14(5). PMID: 24759209
Highly Cited. Review.
Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer.
Cassandra L Hodgkinson, Christopher J Morrow, +23 authors, Caroline Dive.
Nat Med, 2014 Jun 02; 20(8). PMID: 24880617
Highly Cited.
BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer.
Olafur A Stefansson, Alberto Villanueva, +2 authors, Manel Esteller.
Epigenetics, 2012 Oct 17; 7(11). PMID: 23069641    Free PMC article.
RNA helicase A is a downstream mediator of KIF1Bβ tumor-suppressor function in neuroblastoma.
Zhi Xiong Chen, Karin Wallis, +10 authors, Susanne Schlisio.
Cancer Discov, 2014 Jan 29; 4(4). PMID: 24469107
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.
Sonja J Heidorn, Carla Milagre, +8 authors, Richard Marais.
Cell, 2010 Feb 10; 140(2). PMID: 20141835    Free PMC article.
Highly Cited.
Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.
Anchit Khanna, John E Pimanda, Jukka Westermarck.
Cancer Res, 2013 Nov 10; 73(22). PMID: 24204027
Highly Cited. Review.
BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling.
Berta Sanchez-Laorden, Amaya Viros, +12 authors, Richard Marais.
Sci Signal, 2014 Mar 29; 7(318). PMID: 24667377
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.